Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group

Paola Guglielmelli, PhDMD, Giada Rotunno, MSc, PhD, Annalisa Pacilli, PhD, Elisa Rumi, MD, Vittorio Rosti, Federica Delaini, MD, Margherita Maffioli, MD, Tiziana Fanelli, MSc, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Daniela Pietra, PhD, Silvia Salmoiraghi, BSc, Carmela Mannarelli, MSc, PhD, Francesco Passamonti, MD, Alessandro Rambaldi, MD, Giovanni Barosi, Tiziano Barbui, MD, Mario Cazzola, MD, Alessandro M. Vannucchi, MD

Blood (2016) 128 (22): 943.

https://doi.org/10.1182/blood.V128.22.943.943

Published: 2016

Journal Articles

A Study of the Role of Antiplatelet Therapy in the Prevention of Thrombosis in Patients with Calr -Mutated Low Risk Essential Thrombocythemia

Blood (2015) 126 (23): 1602.

https://doi.org/10.1182/blood.V126.23.1602.1602

Published: 2015

Journal Articles

Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis

Ayalew Tefferi, MD, Paola Guglielmelli, PhDMD, Terra L. Lasho, PhD, Yoseph Elala, MD, Tiziana Fanelli, MSc, Naseema Gangat, MBBS, Christy Finke, BS, Giada Rotunno, MSc, Curtis A. Hanson, MD, Rhett P. Ketterling, MD, Animesh Pardanani, MBBS, PhD, Alessandro M. Vannucchi, MD

Blood (2015) 126 (23): 2801.

https://doi.org/10.1182/blood.V126.23.2801.2801

Published: 2015

Journal Articles

Calreticulin Mutation Does Not Modify the International Prognostic Score for Predicting the Risk of Thrombosis Among 1,150 Patients with Essential Thrombocythemia

Guido Finazzi, MD, Alessandra Carobbio, MSc, Paola Guglielmelli, PhDMD, Elisa Rumi, MD, Silvia Salmoiraghi, BiolSc, Alessandro M. Vannucchi, MD, Mario Cazzola, MD, Francesco Passamonti, MD, Alessandro Rambaldi, MD, Tiziano Barbui, MD

Blood (2014) 124 (21): 404.

https://doi.org/10.1182/blood.V124.21.404.404

Published: 2014

Journal Articles

Integration of Mutations and Karyotype Towards a Genetics-Based Prognostic Scoring System (GPSS) for Primary Myelofibrosis

Ayalew Tefferi, MD, Paola Guglielmelli, PhDMD, Christy Finke, BS, Terra L Lasho, PhD, Naseema Gangat, MD, Rhett Ketterling, MD, Curtis A. Hanson, MD, Animesh Pardanani, MBBS, PhD, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 406.

https://doi.org/10.1182/blood.V124.21.406.406

Published: 2014

NARROW

Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group

A Study of the Role of Antiplatelet Therapy in the Prevention of Thrombosis in Patients with Calr -Mutated Low Risk Essential Thrombocythemia

Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis

Calreticulin Mutation Does Not Modify the International Prognostic Score for Predicting the Risk of Thrombosis Among 1,150 Patients with Essential Thrombocythemia

Integration of Mutations and Karyotype Towards a Genetics-Based Prognostic Scoring System (GPSS) for Primary Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group

A Study of the Role of Antiplatelet Therapy in the Prevention of Thrombosis in Patients with Calr -Mutated Low Risk Essential Thrombocythemia

Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis

Calreticulin Mutation Does Not Modify the International Prognostic Score for Predicting the Risk of Thrombosis Among 1,150 Patients with Essential Thrombocythemia

Integration of Mutations and Karyotype Towards a Genetics-Based Prognostic Scoring System (GPSS) for Primary Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only